$41.71 -1.23 (%) Neurocrine Biosciences Inc - NASDAQ

Dec. 8, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Battleground: Alnylam Plunges After Revusiran Pulled, But Some See Opportunity

    TalkMarkets | Oct. 6, 2016 | 19:50PM EST
  2. Icahn School Of Medicine At Mount Sanai Files Complaint Against Neurocrine Sciences For Breach Of Contract - 8-K Filings

    Benzinga | Dec. 2, 2015 | 17:07PM EST
  3. Neurocrine moves up on trial

    IBD | Oct. 8, 2015 | 17:43PM EST
  4. Neurocrine Tardive Dyskinesia Drug Hits, Stock Jumps

    IBD | Oct. 8, 2015 | 10:33AM EST
  5. Stock Futures Down, But Not Much; Domino's Dives, EMC Advances

    IBD | Oct. 8, 2015 | 08:03AM EST
  6. Teva's Auspex Buyout Pays, But Mylan Bid Hits Snag

    IBD | Jun. 16, 2015 | 14:39PM EST
  7. NEUROCRINE BIOSCIENCES

    IBD | Jun. 8, 2015 | 18:01PM EST
  8. Stocks Hitting 52-Week Highs

    Benzinga | Jan. 15, 2015 | 10:25AM EST
  9. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

    Benzinga | Jan. 13, 2015 | 11:34AM EST
  10. AbbVie Stock Down After Guidance, Downgrade

    IBD | Jan. 9, 2015 | 11:49AM EST
  11. Mid-Morning Market Update: Markets Jump; Family Dollar Profit Misses Estimates

    Benzinga | Jan. 8, 2015 | 11:39AM EST
  12. Benzinga's Volume Movers

    Benzinga | Jan. 8, 2015 | 10:33AM EST
  13. Stocks Hitting 52-Week Highs

    Benzinga | Jan. 8, 2015 | 10:22AM EST
  14. Morning Market Gainers

    Benzinga | Jan. 8, 2015 | 09:45AM EST
  15. Pharmaceuticals, Therapeutics And A Retailer On The Move Thursday Morning

    Benzinga | Jan. 8, 2015 | 09:00AM EST
  16. Benzinga's Top #PreMarket Gainers

    Benzinga | Jan. 8, 2015 | 08:12AM EST
  17. What Investors Expect From Neurocrine Biosciences' Next Drug Announcement

    Benzinga | Jan. 2, 2015 | 14:53PM EST
  18. Neurocrine Biosciences Reports Expansion of Clinical Pipeline

    Benzinga | Dec. 10, 2014 | 08:02AM EST
  19. Events for the Week of Nov. 17-21, 2014

    Benzinga | Nov. 17, 2014 | 13:13PM EST
  20. Neurocrine Initiates Tourette Syndrome Clinical Trial

    Benzinga | Oct. 2, 2014 | 15:03PM EST
  21. US Stock Futures Tumble Ahead Of Durable-Goods Orders, Jobless Claims Data

    Benzinga | Feb. 27, 2014 | 07:18AM EST
  22. Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX

    GuruFocus | Jan. 13, 2014 | 08:46AM EST
  23. Benzinga's Top #PreMarket Losers

    Benzinga | Jan. 8, 2014 | 08:20AM EST
  24. Mid-Afternoon Market Update: Markets Post Large Rally as Textron Falls on Citron Report

    Benzinga | Jan. 7, 2014 | 15:43PM EST
  25. Mid-Morning Market Update: Markets Open Higher; IHS Profit Beats Estimates

    Benzinga | Jan. 7, 2014 | 11:38AM EST
  26. Benzinga's Volume Movers

    Benzinga | Jan. 7, 2014 | 11:03AM EST
  27. Morning Market Movers

    Benzinga | Jan. 7, 2014 | 10:07AM EST
  28. Stock Futures Positive, Steady; Netflix Dives On Downgrade

    IBD | Jan. 7, 2014 | 09:03AM EST
  29. Benzinga's Top #PreMarket Gainers

    Benzinga | Jan. 7, 2014 | 08:07AM EST
  30. Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study

    Benzinga | Jan. 6, 2014 | 16:02PM EST
  31. Kilroy Realty Acquires Premier Del Mar Office Campus for Approximately $126M

    Benzinga | Sep. 19, 2013 | 18:20PM EST
  32. Market Wrap For Tuesday, September 10: Once Again, China Moves Markets Higher

    Benzinga | Sep. 10, 2013 | 15:22PM EST
  33. Mid-Afternoon Market Update: Apple Releases Two New iPhones, SolarCity Rallies on New Contract

    Benzinga | Sep. 10, 2013 | 14:46PM EST
  34. Mid-Day Market Update: Five Below Shares Gain On Upbeat Results; Urban Outfitters Tumbles

    Benzinga | Sep. 10, 2013 | 11:59AM EST
  35. Mid-Morning Market Update: Markets Rise; McDonald's Global Same-Store Sales Increase 1.9%

    Benzinga | Sep. 10, 2013 | 10:04AM EST
  36. Morning Market Losers

    Benzinga | Sep. 10, 2013 | 09:24AM EST
  37. Benzinga's Top Pre-Market Losers

    Benzinga | Sep. 10, 2013 | 07:14AM EST
  38. UPDATE: Deutsche Bank Raises PT on Neurocrine Biosciences Ahead of Key Catalysts

    Benzinga | Aug. 29, 2013 | 07:55AM EST
  39. Neurocrine shares

    IBD | Aug. 21, 2013 | 17:43PM EST
  40. Neurocrine Stock Jumps As Cowen Touts Dyskinesia Drug

    IBD | Aug. 21, 2013 | 11:45AM EST
  41. UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Neurocrine Biosciences After Earnings Report

    Benzinga | Feb. 11, 2013 | 04:40AM EST
  42. Stocks Hitting 52-Week Highs

    Benzinga | Feb. 11, 2013 | 03:30AM EST
  43. Neurocrine Biosciences Inc. Reports Operating Results (10-K)

    GuruFocus | Feb. 8, 2013 | 18:36PM EST
  44. Earnings Scheduled For February 8, 2013

    Benzinga | Feb. 7, 2013 | 19:31PM EST
  45. Mid-Afternoon Market Update: Markets Edge Toward Record Highs, Arch Coal Falls Further

    Benzinga | Feb. 5, 2013 | 08:57AM EST
  46. Neurocrine Biosciences Inc. Reports Operating Results (10-Q)

    GuruFocus | Oct. 31, 2012 | 12:33PM EST
  47. UPDATE: Morgan Stanley Initiates Neurocrine Biosciences at Overweight on Asset Quality

    Benzinga | Oct. 4, 2012 | 07:39AM EST
  48. Neurocrine Biosciences Announces Urocortin 2 Phase II Study Results in Patients With Acute Decompensated Heart Failure; Drug Generally Well Tolerated

    Benzinga | May. 17, 2012 | 09:06AM EST
  49. Neurocrine Biosciences Inc. Reports Operating Results (10-K)

    GuruFocus | Feb. 9, 2012 | 07:02AM EST
  50. Top 5 Small-Cap Drug Firms Include Questcor, Cubist

    IBD | Feb. 3, 2012 | 02:14AM EST
Trading Center